Author

A. Borowsky

Observed name: A. D. Borowsky

Institution: University of California, San Francisco

Observed institution: University of California, San Francisco

OpenAlex ID: A5126201893

Abstract RF5-06: Pathologic complete response rates (pCR) after the novel HER2 ADC ARX788: Results from the I-SPY2.2 trial

2026 · P. R. Pohlmann, H. S. Rugo, et al. · Clinical Cancer Research

Abstract GS3-07: Risk-based breast cancer screening is safe, preferred by women and identifies highest risk individuals: Results from WISDOM 1.0

2026 · L. J. Esserman, A. S. Fiscalini, et al. · Clinical Cancer Research

Abstract PS4-02-01: Differential early response to neoadjuvant endocrine therapy in lobular versus non-lobular breast cancer on the Endocrine Optimization Pilot (EOP) of the I-SPY2 Trial

2026 · R. Mukhtar, P. Norwood, et al. · Clinical Cancer Research

Abstract PS3-03-08: Initial results from RECAST DCIS: Multicenter platform trial testing active surveillance and novel endocrine therapy agents for DCIS management

2026 · K. C. Hewitt, C. Yau, et al. · Clinical Cancer Research

Works count: 4

Citation count:

H-index:

I10-index: